Insulin Therapy A Predictor of Mortality in Coronary Artery Disease – (05-03-01)



Insulin Therapy A Predictor of Mortality in Coronary Artery Disease

I’ve touched on this many times before–insulin is really not a friendly hormone to the body. It is designed to be short acting and then cleared from the system, but with today’s lifestyle this just does not happen and levels run high. Study after study have demonstrated damaging effects from hyperinsulinemia. Based on this, the results of this study are not surprising.

50th scientific session of the American College of Cardiology Insulin therapy is associated with a very high risk of death for diabetics with cardiovascular disease. Farangis Lavasani and colleagues at Latter Day Saints Hospital in Salt Lake City, Utah, analyzed mortality data in 1428 patients with diabetes and documented coronary artery disease who had been admitted to their institution for angiography. Nearly all patients had at least 70% stenosis in at least one coronary artery, she noted. The investigators did not differentiate between type 1 and type 2 diabetes. After 2.5 years of followup, Lavasani reported, patients on insulin had a mortality rate of 28%, those on sulfonylureas a mortality rate of 16%, those on a glitazone a mortality rate of 14% and those on metformin a mortality rate of 8%. “Metformin improves survival” in patients with both diabetes and cardiovascular disease, Lavasani said. She told Reuters Health that it appears that adding a sulfonylurea to metformin appears to diminish the efficacy of the insulin-sensitizing therapy.

James Bogash

For more than a decade, Dr. Bogash has stayed current with the medical literature as it relates to physiology, disease prevention and disease management. He uses his knowledge to educate patients, the community and cyberspace on the best way to avoid and / or manage chronic diseases using lifestyle and targeted supplementation.







Email: